Drug prohibition law

Statement by Minister Lametti on Royal Assent of legislation that addresses systemic racism and discrimination in the criminal justice system

Retrieved on: 
Friday, November 18, 2022
Drug prohibition law, Adult, Correctional Service of Canada, Canadian House of Commons Standing Committee on Justice and Human Rights, House, Statistics Canada, The Honourable, Psychoactive Substances Act 2016, The Criminal Code, Legislation, Royal assent, Senate, Commons, Mental health, Criminal code, MMP, Risk, Justice, Emotion, Controlled Drugs and Substances Act, Police

These sentencing reforms will help address the overrepresentation of Indigenous people, Black persons, racialized Canadians, and members of marginalized communities in the criminal justice system.

Key Points: 
  • These sentencing reforms will help address the overrepresentation of Indigenous people, Black persons, racialized Canadians, and members of marginalized communities in the criminal justice system.
  • "Systemic racism is a reality for too many in Canada's criminal justice system.
  • These reforms will ensure a fairer, more effective justice system for all, while maintaining public safety.
  • "These evidence-based reforms address systemic racism and discrimination in our criminal justice system and keep communities safe by reducing the risk of re-offending.

Braxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders

Retrieved on: 
Tuesday, November 1, 2022
Rapids, SEDAR, News, CSE, DMCL, Drug prohibition law, CDSA, Ketamine, Person, Circular, Health Canada, Removal of cannabis from Schedule I of the Controlled Substances Act, Controlled Drugs and Substances Act, Company, Psilocybin, Disorder, Multimedia, Forward-looking statement, Euro-Excellence Inc v Kraft Canada Inc, Depression, Risk, Pharmaceutical industry, Audit

For more details on the matters covered at the annual meeting, please refer to the Company's management information circular available on SEDAR at www.sedar.com .Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.

Key Points: 
  • For more details on the matters covered at the annual meeting, please refer to the Company's management information circular available on SEDAR at www.sedar.com .Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.
  • Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.
  • Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others.
  • Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform.

HYTN Awarded Controlled Drugs and Substances Dealer’s License Allowing for Production and Sale of Psilocybin

Retrieved on: 
Monday, October 17, 2022
Physician, Time, Cannabis, Substance, Sale, Transport, Growth, Achievement, Standard, ISO 9001:2015, Fungus, License, Biomass, Health Canada, Company, Drug prohibition law, CSE, Kelowna, Psilocybin, GLOBE, Clinical trial, Drug, Pharmaceutical industry

This announcement follows several license achievements including a Standard Processing License and its Amendment for Sale, a Cannabis Research License, a Standard Cultivation License, and a Medical Sales License (with possession).

Key Points: 
  • This announcement follows several license achievements including a Standard Processing License and its Amendment for Sale, a Cannabis Research License, a Standard Cultivation License, and a Medical Sales License (with possession).
  • This is a considerable achievement, said Elliot McKerr, HYTN Chief Executive Officer.
  • Anticipating the evolving landscape of controlled substance access is paramount to ensuring HYTN is at the forefront of product development and future revenue opportunities.
  • HYTN intends to begin researching and developing psilocybin-based products that complement its current offerings of cannabis beverages and edibles.

KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle the Growing Mental Health Crisis and Shortage of Mental Health Care Providers

Retrieved on: 
Tuesday, October 4, 2022
Post-traumatic stress disorder, OTC, National Alliance on Mental Illness, Anxiety, News, Tropical Storm Ian, Telehealth, Lists of diseases, Euro-Excellence Inc v Kraft Canada Inc, National Alliance, Psychiatry, National Helping Families in Mental Health Crisis Day, National Suicide Prevention Week, Psilocybin, CEO, Ketamine, Population, CSE, Multimedia, Disorder, COVID-19, Mental disorder, Risk, Awareness, Growth, CDSA, The Journal of Clinical Psychiatry, Clifford Whittingham Beers, Rapids, Quality of life, Controlled Drugs and Substances Act, Journal, Suicidal ideation, Patient, Person, Drug prohibition law, Diagnosis, Removal of cannabis from Schedule I of the Controlled Substances Act, Forward-looking statement, Intention, Mental health, Depression, Company, Mental Illness Awareness Week, Pharmaceutical industry, Medicine, Audit

KetaMD is committed to battling the growing mental health crisis and alleviating the growing shortage of mental health care providers in Florida and across America, both issues further exacerbated by the COVID-19 pandemic.

Key Points: 
  • KetaMD is committed to battling the growing mental health crisis and alleviating the growing shortage of mental health care providers in Florida and across America, both issues further exacerbated by the COVID-19 pandemic.
  • Mental Health Crisis by the Numbers:
    1 in 5 U.S. adults experience mental illness each year.
  • Over 6.3 million people in Florida live in a community that does not have enough mental health professionals.
  • Florida ranks 49th in the nation for access to mental health care, according to Mental Health America.

Village Farms International Recognized for Canadian Cannabis Business

Retrieved on: 
Monday, September 26, 2022
Safety, Efficiency, Delta 3 greenhouse, Rose, EBITDA, Compliance, Business, Drug prohibition law, Securities Act of 1933, The Globe and Mail, NASDAQ, Tax, Budget, Controlled Drugs and Substances Act, COVID-19, Food, Company, Acquisition, Growth, Public expenditure, Controlled Environments Magazine, Transport, Press release, United States Department of Agriculture, Food and Drug Administration, Securities Exchange Act of 1934, Netherlands, Forward-looking statement, CEO, Criminal code, Conference, Globe, Removal of cannabis from Schedule I of the Controlled Substances Act, Health, Cannabinoid, Fast-moving consumer goods, LLC, The Criminal Code, Cannabis, Private Securities Litigation Reform Act, Drug, CBD, BC

Village Farms Named Best Canadian Cannabis Company at 15th Benzinga Cannabis Capital Conference; CEO Michael DeGiglio Featured as Keynote

Key Points: 
  • Village Farms Named Best Canadian Cannabis Company at 15th Benzinga Cannabis Capital Conference; CEO Michael DeGiglio Featured as Keynote
    VANCOUVER, BC, Sept. 26, 2022 /PRNewswire/ - Village Farms International, Inc. ("Village Farms" or the "Company") (NASDAQ: VFF) today announced its wholly owned subsidiary, Pure Sunfarms, ranked as the 17th fastest growing company by the Globe and Mail's Report on Business, which named Canada's Top Growing Companies across all industry sectors.
  • "Each recognition of the performance of our Canadian Cannabis business further highlights the strength and success of the Village Farms model and strategy in the cannabis industry," said Michael DeGiglio, Chief Executive Officer, Village Farms.
  • Village Farms was named Best Canadian Cannabis Company at the first Benzinga Cannabis Awards, which were presented at the 15th Benzinga Cannabis Capital Conference on September 13 and 14, 2022 in Chicago.
  • "I am so proud and honoured to accept this award on behalf of the entire Village Farms Canadian cannabis team," said Mr. DeGiglio.

Braxia Scientific Announces Board Appointment

Retrieved on: 
Thursday, September 22, 2022
Removal of cannabis from Schedule I of the Controlled Substances Act, Regional Municipality of Waterloo, Bipolar disorder, Ketamine, Rapids, Telehealth, Intention, Psilocybin, Company, Growth, News, COO, Person, Forward-looking statement, Risk, OTC, CSE, Technology, Disorder, Lists of diseases, Euro-Excellence Inc v Kraft Canada Inc, Drug prohibition law, Anxiety, Post-traumatic stress disorder, Multimedia, PTSD, CDSA, Depression, Controlled Drugs and Substances Act, Pharmaceutical industry, Audit

TORONTO, Sept. 21, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce that Leann Taylor, President and COO of KetaMD, Inc. ("KetaMD"), has joined the board of directors.

Key Points: 
  • TORONTO, Sept. 21, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce that Leann Taylor, President and COO of KetaMD, Inc. ("KetaMD"), has joined the board of directors.
  • KetaMD, a telemedicine platform recently acquired by Braxia Scientific, provides access to at-home ketamine treatments for people suffering from mental health disorders such as depression, bipolar disorder, anxiety and post-traumatic stress disorder (PTSD).
  • Braxia Scientific is a medical research and telemedicine company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.
  • Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others.

Braxia Scientific Announces Court Approval of Class Action Settlement in Canada

Retrieved on: 
Saturday, September 17, 2022
Settlement, Removal of cannabis from Schedule I of the Controlled Substances Act, Regional Municipality of Waterloo, Ketamine, Controlled Drugs and Substances Act, Central District, Law of the United Kingdom, Rapids, Telehealth, Psilocybin, Company, CDN, Supreme court, News, Person, Forward-looking statement, USD, Risk, OTC, Health Canada, CSE, Technology, Lists of diseases, Euro-Excellence Inc v Kraft Canada Inc, Drug prohibition law, US, Insurance, District court, Multimedia, CDSA, Depression, Online gambling, Generic drug, Pharmaceutical industry, Audit

TORONTO, Sept. 16, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) announced today that the Supreme Court of British Columbia has approved a settlement of a class action lawsuit that was filed in May 2021 against Braxia Scientific, its CEO, certain of its former officers, a shareholder, and underwriters (the "Canadian Settlement").

Key Points: 
  • TORONTO, Sept. 16, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) announced today that the Supreme Court of British Columbia has approved a settlement of a class action lawsuit that was filed in May 2021 against Braxia Scientific, its CEO, certain of its former officers, a shareholder, and underwriters (the "Canadian Settlement").
  • The court approval of an agreement in principle (the "US Settlement") to settle claims alleged in a securities class action (the "US Class Action") against the Company and certain of its former officers filed in the United States District Court for the Central District of California in April, 2021, remains pending.
  • The US Settlement contemplates a cash payment by the Company of USD $1 million to settle the US Class Action.
  • After available insurance, and assuming the court approval of the US Settlement is obtained, the total cost to the Company to settle both class actions will be approximately CDN $1.36million.

Braxia Scientific Launches KetaMD in Florida; First Patients Complete Initial Virtual Ketamine Treatments At-Home

Retrieved on: 
Monday, September 12, 2022
Removal of cannabis from Schedule I of the Controlled Substances Act, Regional Municipality of Waterloo, Bipolar disorder, Ketamine, COVID-19, Rapids, Telehealth, Intention, Psilocybin, Company, Growth, News, National Suicide Prevention Week, Forward-looking statement, Patient, Mental health, Risk, OTC, CEO, Health Canada, CSE, Technology, Disorder, Lists of diseases, Euro-Excellence Inc v Kraft Canada Inc, Drug prohibition law, Anxiety, Diagnosis, Post-traumatic stress disorder, Multimedia, PTSD, CDSA, Depression, Controlled Drugs and Substances Act, Medicine, Pharmaceutical industry, Audit

KetaMD onboarded new patients and completed initial ketamine treatments.

Key Points: 
  • KetaMD onboarded new patients and completed initial ketamine treatments.
  • Dr. Roger McIntyre commented, "We are incredibly proud to have treated our first patients in the U.S. through our KetaMD platform.
  • KetaMD is a HIPAA-compliant telemedicine platform providing affordable and potentially life-changing at-home medical ketamine treatments.
  • Braxia Scientific is a medical research and telemedicine company with clinics that provide innovative ketamine and psilocybin treatments for people with depression and related disorders.

Braxia Scientific to Present at H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022

Retrieved on: 
Friday, September 9, 2022
CEO, Technology, CSE, OTC, Psilocybin, Euro-Excellence Inc v Kraft Canada Inc, Telehealth, Disorder, Removal of cannabis from Schedule I of the Controlled Substances Act, Rapids, Regional Municipality of Waterloo, Lists of diseases, Person, Risk, Drug prohibition law, Health Canada, Multimedia, Ketamine, Depression, Controlled Drugs and Substances Act, Intention, Conference, CDSA, Company, News, Growth, Forward-looking statement, Pharmaceutical industry, Audit

TORONTO, Sept. 9, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Annual Global Investment Conference being held in New York, September 12-14, 2022.

Key Points: 
  • TORONTO, Sept. 9, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Annual Global Investment Conference being held in New York, September 12-14, 2022.
  • Dr. McIntyre will also be available to host one-on-one meetings with institutional investors registered with H.C. Wainwright.
  • Braxia Scientific is a medical research and telemedicine company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.
  • Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others.

Government of Canada takes action at the border to help address toxic illegal drug supply in Canada

Retrieved on: 
Thursday, September 1, 2022
Harm reduction, Canada Border Services Agency, Dutch Association of Mental Health and Addiction Care, Government, Death, Controlled Substances Act, Fentanyl, Toxicity, Drug prohibition law, Salt, Controlled Drugs and Substances Act, Addiction, Government of Canada, History, CBSA, Mental health, Narcotic, Drug, Medical device, Health

The Government of Canada continues to work with its partners to help reduce the toxicity of the illegal drug supply in Canada.

Key Points: 
  • The Government of Canada continues to work with its partners to help reduce the toxicity of the illegal drug supply in Canada.
  • Illegal drug producers often deliberately engineer substances to circumvent existing international and domestic control measures.
  • "The Canada Border Services Agency has various tools in place to keep Canadians safe from illegal substances entering our country.
  • The Government of Canada works with domestic and international partners to address the toxic illegal drug supply, including by:
    Providing border services officers with tools and equipment to safely and effectively detect, identify and interdict fentanyl and other toxic substances at the border.